SCHEMBL20704342

SCHEMBL20704342

Cc1c(Cl)cnc(O)c1Br

nearest known ligand 0.39

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PLAU P00749 1/20 0.39
DAO P14920 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28793349 0.79 PLAU (0.42) PLAUDAO
SCHEMBL31440837 0.77 DAO (0.37) PLAUDAO
SCHEMBL26616054 0.77 CCR1 (0.38)
SCHEMBL30631398 0.77 CCR1 (0.38)
SCHEMBL31613426 0.77
SCHEMBL26615878 0.77 DAO (0.37) PLAUDAO
SCHEMBL31240890 0.74 LMNA (0.41) PLAUDAO
SCHEMBL18326515 0.73 PLAU (0.37) PLAUDAO
SCHEMBL9455819 0.73 PLAU (0.46) PLAUDAO
SCHEMBL676712 0.71 DAO (0.33) PLAUDAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503439-B2 Heteroaryl compounds for the treatment of pain VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-12-23 US disclosed
CN-119677737-A Heteroaryl compounds for the treatment of pain 沃泰克斯药物股份有限公司 2025-03-21 CN disclosed
EP-4511116-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Vertex Pharmaceuticals Incorporated (US) 2025-02-26 EP disclosed
US-20230373925-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-23 US disclosed
US-20230373925-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-23 US disclosed
US-20230373925-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-23 US disclosed
WO-2023205463-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 WO disclosed
WO-2023205463-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 WO disclosed
CN-110997656-B Substituted indole compounds useful as TLR7/8/9 inhibitors 百时美施贵宝公司 2023-04-14 CN disclosed
US-11447466-B2 Substituted indole compounds useful as inhibitors of TLR7/8/9 BRISTOL-MYERS SQUIBB COMPANY (US) 2022-09-20 US disclosed
EP-3661926-B1 SUBSTITUTED INDOLE COMPOUNDS USEFUL AS INHIBITORS OF TLR7/8/9 BRISTOL MYERS SQUIBB CO (US) 2022-02-23 EP disclosed
US-20200239437-A1 SUBSTITUTED INDOLE COMPOUNDS USEFUL AS INHIBITORS OF TLR7/8/9 BRISTOL MYERS SQUIBB CO (US) 2020-07-30 US disclosed
EP-3661926-A1 SUBSTITUTED INDOLE COMPOUNDS USEFUL AS INHIBITORS OF TLR7/8/9 Bristol-Myers Squibb Company (US) 2020-06-10 EP disclosed
CN-110997656-A Substituted indole compounds useful as inhibitors of TLR7/8/9 百时美施贵宝公司 2020-04-10 CN disclosed
WO-2019028302-A1 SUBSTITUTED INDOLE COMPOUNDS USEFUL AS INHIBITORS OF TLR7/8/9 BRISTOL-MYERS SQUIBB COMPANY (US) 2019-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373925-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN TRPV1, SCN3A, KCNN3 PLAU 3797/4885DAO 2767/4885
US-12503439-B2 Heteroaryl compounds for the treatment of pain TRPV1, SCN3A, KCNN3 PLAU 3797/4885DAO 2767/4885
US-11447466-B2 Substituted indole compounds useful as inhibitors of TLR7/8/9 TLR7, TLR9, TLR8 PLAU 4500/4885DAO 1693/4885
US-20200239437-A1 SUBSTITUTED INDOLE COMPOUNDS USEFUL AS INHIBITORS OF TLR7/8/9 TLR7, TLR9, TLR8 PLAU 4500/4885DAO 1693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.